Margaret Porter-Scott

发表

Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 Tool Compound.

Tim J. Wigle, K. Swinger, T. Riera, 2015, ACS medicinal chemistry letters.

277 The discovery and pre-clinical development of the first clinical stage EZH2-inhibitor, EPZ-6438 (E7438)

Tim J. Wigle, R. Copeland, R. Pollock, 2014 .

Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma

Tim J. Wigle, Yonghong Xiao, R. Copeland, 2014, Molecular Cancer Therapeutics.

The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat.

R. Copeland, R. Pollock, V. Richon, 2016, Journal of medicinal chemistry.

Mutant Non-Hodgkin Lymphoma EZH 2 Activity in Selective Inhibition of EZH 2 by EPZ-6438 Leads to Potent Antitumor

Yonghong Xiao, R. Copeland, N. Waters, 2014 .

Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas

R. Copeland, R. Pollock, B. Littlefield, 2014, PloS one.

Identification of a First-in-Class PRMT5 Inhibitor with Potent in Vitro and in Vivo Activity in Preclinical Models of Mantle Cell Lymphoma

Lei Jin, R. Copeland, Elayne Penebre, 2014 .

Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma

Yonghong Xiao, R. Copeland, N. Waters, 2014, Molecular Cancer Therapeutics.

The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat.

R. Copeland, R. Pollock, V. Richon, 2016, Journal of medicinal chemistry.